JP3782591B2 - 置換イソキノリン−3−カルボキサミド、その製法および薬剤としてのその使用 - Google Patents

置換イソキノリン−3−カルボキサミド、その製法および薬剤としてのその使用 Download PDF

Info

Publication number
JP3782591B2
JP3782591B2 JP29701198A JP29701198A JP3782591B2 JP 3782591 B2 JP3782591 B2 JP 3782591B2 JP 29701198 A JP29701198 A JP 29701198A JP 29701198 A JP29701198 A JP 29701198A JP 3782591 B2 JP3782591 B2 JP 3782591B2
Authority
JP
Japan
Prior art keywords
hydrogen
chlorine
formula
alkoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP29701198A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11302257A (ja
JPH11302257A5 (cg-RX-API-DMAC7.html
Inventor
クラウス・ヴアイトマン
カール−ハインツ・バリングハウス
ゲオルク・チヤンク
ウルリヒ・ヴエルナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of JPH11302257A publication Critical patent/JPH11302257A/ja
Publication of JPH11302257A5 publication Critical patent/JPH11302257A5/ja
Application granted granted Critical
Publication of JP3782591B2 publication Critical patent/JP3782591B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP29701198A 1997-10-20 1998-10-19 置換イソキノリン−3−カルボキサミド、その製法および薬剤としてのその使用 Expired - Lifetime JP3782591B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19746287A DE19746287A1 (de) 1997-10-20 1997-10-20 Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287:1 1997-10-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005254578A Division JP4691419B2 (ja) 1997-10-20 2005-09-02 置換イソキノリン−3−カルボキサミド、その製法および薬剤としてのその使用

Publications (3)

Publication Number Publication Date
JPH11302257A JPH11302257A (ja) 1999-11-02
JPH11302257A5 JPH11302257A5 (cg-RX-API-DMAC7.html) 2005-10-27
JP3782591B2 true JP3782591B2 (ja) 2006-06-07

Family

ID=7846053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP29701198A Expired - Lifetime JP3782591B2 (ja) 1997-10-20 1998-10-19 置換イソキノリン−3−カルボキサミド、その製法および薬剤としてのその使用
JP2005254578A Expired - Lifetime JP4691419B2 (ja) 1997-10-20 2005-09-02 置換イソキノリン−3−カルボキサミド、その製法および薬剤としてのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005254578A Expired - Lifetime JP4691419B2 (ja) 1997-10-20 2005-09-02 置換イソキノリン−3−カルボキサミド、その製法および薬剤としてのその使用

Country Status (24)

Country Link
US (1) US6093730A (cg-RX-API-DMAC7.html)
EP (2) EP1538160B1 (cg-RX-API-DMAC7.html)
JP (2) JP3782591B2 (cg-RX-API-DMAC7.html)
KR (1) KR100618922B1 (cg-RX-API-DMAC7.html)
CN (1) CN1117079C (cg-RX-API-DMAC7.html)
AR (1) AR013696A1 (cg-RX-API-DMAC7.html)
AT (2) ATE432940T1 (cg-RX-API-DMAC7.html)
AU (1) AU755714B2 (cg-RX-API-DMAC7.html)
BR (1) BR9804504B1 (cg-RX-API-DMAC7.html)
CA (2) CA2250664A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ337298A3 (cg-RX-API-DMAC7.html)
DE (3) DE19746287A1 (cg-RX-API-DMAC7.html)
DK (2) DK0911340T3 (cg-RX-API-DMAC7.html)
ES (2) ES2245471T3 (cg-RX-API-DMAC7.html)
HU (1) HUP9802422A3 (cg-RX-API-DMAC7.html)
ID (1) ID21115A (cg-RX-API-DMAC7.html)
IL (1) IL126638A0 (cg-RX-API-DMAC7.html)
NO (1) NO312365B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ332363A (cg-RX-API-DMAC7.html)
PL (1) PL192354B1 (cg-RX-API-DMAC7.html)
PT (1) PT911340E (cg-RX-API-DMAC7.html)
SG (1) SG87776A1 (cg-RX-API-DMAC7.html)
TR (1) TR199802106A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA989505B (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275014A1 (en) * 2000-05-30 2001-12-11 Neurogen Corporation Imidazoloisoquinolines
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
HU229475B1 (en) 2001-12-06 2014-01-28 Fibrogen Methods of increasing endogenous erythropoietin (epo)
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2005007192A2 (en) * 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CN103145616B (zh) * 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
CN101849943A (zh) * 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
AU2006326662B2 (en) 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
CN102351791B (zh) 2006-01-27 2014-10-29 菲布罗根有限公司 使低氧诱导因子(hif)稳定的氰基异喹啉化合物
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
KR100934671B1 (ko) * 2006-03-30 2009-12-31 엘지전자 주식회사 비디오 신호를 디코딩/인코딩하기 위한 방법 및 장치
AU2007234408B2 (en) 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
NZ623002A (en) 2006-06-26 2015-08-28 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
WO2008076427A2 (en) 2006-12-18 2008-06-26 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
US8048892B2 (en) 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2142509B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
CA2685219C (en) 2007-05-04 2012-06-19 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
CN101497584B (zh) * 2008-01-29 2010-12-22 首都医科大学 异喹啉-3-甲酰氨基酸苄酯及其制备和应用
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
US8283465B2 (en) * 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
NO2686520T3 (cg-RX-API-DMAC7.html) 2011-06-06 2018-03-17
CA2842730C (en) * 2011-07-22 2018-08-21 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
ES2818977T3 (es) 2011-10-25 2021-04-14 Janssen Pharmaceutica Nv Método para obtener cristales de sal de meglumina de ácido 1-(5,6-dicloro-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-carboxílico
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
EP3470397B1 (en) 2012-07-16 2021-12-29 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SG11201500234YA (en) 2012-07-16 2015-02-27 Fibrogen Inc Process for making isoquinoline compounds
US9822135B2 (en) 2012-10-30 2017-11-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 dimerization inhibitors
SG10202009266PA (en) 2013-01-24 2020-10-29 Fibrogen Inc Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
HUE066123T2 (hu) 2013-06-13 2024-07-28 Akebia Therapeutics Inc Készítmények és módszerek anémia kezelésére
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途
MX384843B (es) 2014-05-15 2025-03-14 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
NZ735973A (en) 2015-04-01 2023-06-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
EP4667059A3 (en) * 2015-05-28 2026-04-08 Japan Tobacco Inc. Method for treating or preventing diabetic nephropathy
ES2898340T3 (es) * 2015-07-09 2022-03-07 Insmed Inc Composiciones y métodos para tratar neumopatías y lesión pulmonar
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
KR20200112872A (ko) * 2018-01-09 2020-10-05 코넬 유니버시티 장기 섬유증의 예방 및 치료
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
EP3829623A4 (en) * 2018-08-03 2022-10-19 Cornell University METHODS OF REDUCING ABNORMAL SCAR FORMATION
TWI865563B (zh) 2019-07-30 2024-12-11 德商拜耳動物保健有限公司 新穎異喹啉衍生物
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
CN112979541B (zh) * 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
CA2085954A1 (en) * 1991-12-24 1993-06-25 Klaus Weidmann Substituted pyridine n-oxides, processes for their preparation, and their use
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4233124A1 (de) * 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE149485T1 (de) * 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
EP0650961B1 (de) * 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2138929A1 (en) * 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid

Also Published As

Publication number Publication date
CA2251647C (en) 2011-08-30
JP2006056894A (ja) 2006-03-02
HK1019605A1 (en) 2000-02-18
AU8941398A (en) 1999-05-06
ES2328156T3 (es) 2009-11-10
NO312365B1 (no) 2002-04-29
DK1538160T3 (da) 2009-10-05
ID21115A (id) 1999-04-22
IL126638A0 (en) 1999-08-17
NO984877L (no) 1999-04-21
CN1218802A (zh) 1999-06-09
DE19746287A1 (de) 1999-04-22
ES2245471T3 (es) 2006-01-01
TR199802106A3 (tr) 1999-05-21
BR9804504B1 (pt) 2009-01-13
CA2251647A1 (en) 1999-04-20
HUP9802422A2 (hu) 1999-08-30
KR19990037182A (ko) 1999-05-25
PL329274A1 (en) 1999-04-26
ATE432940T1 (de) 2009-06-15
EP0911340A2 (de) 1999-04-28
HU9802422D0 (en) 1998-12-28
JPH11302257A (ja) 1999-11-02
US6093730A (en) 2000-07-25
BR9804504A (pt) 2001-05-22
DE59814365D1 (de) 2009-07-16
NZ332363A (en) 2000-04-28
CZ337298A3 (cs) 1999-05-12
ATE299148T1 (de) 2005-07-15
SG87776A1 (en) 2002-04-16
NO984877D0 (no) 1998-10-19
JP4691419B2 (ja) 2011-06-01
KR100618922B1 (ko) 2007-04-25
DE59812907D1 (de) 2005-08-11
CA2250664A1 (en) 1999-04-20
HUP9802422A3 (en) 2002-02-28
TR199802106A2 (xx) 1999-05-21
EP0911340A3 (de) 1999-07-07
ZA989505B (en) 1999-04-20
PT911340E (pt) 2005-09-30
EP1538160A1 (de) 2005-06-08
AR013696A1 (es) 2001-01-10
EP1538160B1 (de) 2009-06-03
AU755714B2 (en) 2002-12-19
CN1117079C (zh) 2003-08-06
PL192354B1 (pl) 2006-10-31
DK0911340T3 (da) 2005-11-07
EP0911340B1 (de) 2005-07-06

Similar Documents

Publication Publication Date Title
JP4691419B2 (ja) 置換イソキノリン−3−カルボキサミド、その製法および薬剤としてのその使用
EP0012845B1 (en) Tetrahydroisoquinoline compounds, process for preparing same and pharmaceutical compositions containing them
US4294832A (en) Tetrahydroisoquinoline compounds and a pharmaceutical composition thereof
TW541316B (en) Prodrugs of thrombin inhibitors
AU743750B2 (en) 3-hydroxypyridine-2-carboxamidoesters, their preparation and their use as pharmaceuticals
KR20000065090A (ko) 3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도
CZ289356B6 (cs) Substituované amidy heterocyklických karboxylových kyselin, způsob jejich přípravy a jejich pouľití jako léčiva
JP2002542164A (ja) 補体プロテアーゼの低分子インヒビター
AU3646993A (en) New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
WO1992018488A1 (en) Novel oxazinone derivative
JPH05507295A (ja) N―(α―置換―ピリジニル)カルボニルジペプチド抗高血圧剤
RO104347B1 (en) Production method of amids acids cyclomethylen - 1,2 - dicarboxylic
US5166154A (en) Imidazo[1,2-a]piperazines
RU2168493C2 (ru) Производные l-аргинина, способ их получения, фармацевтическая композиция, обладающая ингибирующей no-синтазу активностью
SK322003A3 (en) Thrombin inhibitors comprising an aminoisoquinoline group
RU2117660C1 (ru) Сложные эфиры ацилсульфонамидо- и сульфонамидопиридин-2-карбоновой кислоты, содержащая их фармацевтическая композиция и способ ее получения
MXPA98008644A (en) Amques of substitute isoquinolin-3-carboxylic acid, its preparation and its employment as a medicine
KR960008242B1 (ko) 벤조옥사디논유도체
JPS633000A (ja) ペプチド誘導体類及びそれらの製造方法
JP2002522060A (ja) エキソケリンを合成するための新規方法
JP2654848B2 (ja) 新規イソキノリン誘導体またはその酸付加塩
JPH04338330A (ja) チロシン硫酸塩からなる血小板凝集阻止剤
EP0186431A1 (en) Anti-hypertensive octahydro-6-azaindole dipeptide derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050902

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20050902

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20051005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060310

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100317

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110317

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120317

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130317

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term